Literature search services are currently unavailable. During our hosting provider's UPS upgrade we experienced a hardware failure and are currently working to resolve the issue.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice.

In the brain of Alzheimer's disease (AD) patients, neurotoxic amyloid peptides accumulate and are deposited as senile plaques. A major therapeutic strategy aims to decrease production of amyloid peptides by inhibition of gamma-secretase. Presenilins are polytopic transmembrane proteins that are essential for gamma-secretase activity during development and in amyloid production. By loxP/Cre-recombinase-mediated deletion, we generated mice with postnatal, neuron-specific presenilin-1 (PS1) deficiency, denoted PS1(n-/-), that were viable and fertile, with normal brain morphology. In adult PS1(n-/-) mice, levels of endogenous brain amyloid peptides were strongly decreased, concomitant with accumulation of amyloid precursor protein (APP) C-terminal fragments. In the cross of APP[V717I]xPS1 (n-/-) double transgenic mice, the neuronal absence of PS1 effectively prevented amyloid pathology, even in mice that were 18 months old. This contrasted sharply with APP[V717I] single transgenic mice that all develop amyloid pathology at the age of 10-12 months. In APP[V717I]xPS1 (n-/-) mice, long-term potentiation (LTP) was practically rescued at the end of the 2 hr observation period, again contrasting sharply with the strongly impaired LTP in APP[V717I] mice. The findings demonstrate the critical involvement of amyloid peptides in defective LTP in APP transgenic mice. Although these data open perspectives for therapy of AD by gamma-secretase inhibition, the neuronal absence of PS1 failed to rescue the cognitive defect, assessed by the object recognition test, of the parent APP[V717I] transgenic mice. This points to potentially detrimental effects of accumulating APP C99 fragments and demands further study of the consequences of inhibition of gamma-secretase activity. In addition, our data highlight the complex functional relation of APP and PS1 to cognition and neuronal plasticity in adult and aging brain.

Pubmed ID: 11978821


  • Dewachter I
  • ReversĂ© D
  • Caluwaerts N
  • Ris L
  • KuipĂ©ri C
  • Van den Haute C
  • Spittaels K
  • Umans L
  • Serneels L
  • Thiry E
  • Moechars D
  • Mercken M
  • Godaux E
  • Van Leuven F


The Journal of neuroscience : the official journal of the Society for Neuroscience

Publication Data

May 1, 2002

Associated Grants


Mesh Terms

  • Alzheimer Disease
  • Amyloid Precursor Protein Secretases
  • Amyloid beta-Protein Precursor
  • Animals
  • Aspartic Acid Endopeptidases
  • Basic Helix-Loop-Helix Transcription Factors
  • Brain
  • Cognition Disorders
  • Crosses, Genetic
  • DNA-Binding Proteins
  • Disease Models, Animal
  • Electric Stimulation
  • Endopeptidases
  • Hippocampus
  • In Vitro Techniques
  • Intracellular Signaling Peptides and Proteins
  • Long-Term Potentiation
  • Membrane Proteins
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Neuronal Plasticity
  • Neurons
  • Peptide Fragments
  • Phenotype
  • Plaque, Amyloid
  • Presenilin-1
  • RNA, Messenger
  • Recognition (Psychology)
  • Repressor Proteins